Upsher-Smith has expanded its Access Pathways Program to offer commercially insured patients a $0 co-pay and free home delivery for acute and preventive migraine treatment options.
ViiV Healthcare’s Cabenuva is the first Food and Drug Administration-approved injectable that is a complete regimen for HIV-infected adults administered once a month.
Merck will acquire Oncolmmune, which recently announced positive findings from a Phase 3 study of its candidate for the treatment of patients with severe and critical COVID-19.
Genentech’s Xofluza now is indicated to include post-exposure prevention of influenza for patients 12 years old and older after contact with a person with the flu.
Eli Lilly and Incyte have received emergency use authorization from the Food and Drug Administration for baricitinib in combination with remdesivir in hospitalized adult and pediatric patients age 2 years old or older with COVID-19.